167 related articles for article (PubMed ID: 31773936)
21. The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
Mendez LC; Dhar A; Laidley D; Moussa M; Gomez JA; Chin J; Lee TY; Thiessen JD; Hoover D; Surrey K; Helou J; Velker V; Correa RJ; D'Souza D; Bayani J; Bauman G
BMC Cancer; 2023 Apr; 23(1):362. PubMed ID: 37081426
[TBL] [Abstract][Full Text] [Related]
22. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
24. Delayed response after repeated
Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
[TBL] [Abstract][Full Text] [Related]
25. Modeling and Predicting Tumor Response in Radioligand Therapy.
Kletting P; Thieme A; Eberhardt N; Rinscheid A; D'Alessandria C; Allmann J; Wester HJ; Tauber R; Beer AJ; Glatting G; Eiber M
J Nucl Med; 2019 Jan; 60(1):65-70. PubMed ID: 29748236
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
27. Dosimetry Estimate and Initial Clinical Experience with
Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816
[TBL] [Abstract][Full Text] [Related]
28. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
29. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
[TBL] [Abstract][Full Text] [Related]
30. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
31. [
Boegemann M; Schrader AJ; Rahbar K
Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
[TBL] [Abstract][Full Text] [Related]
32. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
33. EANM procedure guidelines for radionuclide therapy with
Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
Mayor N; Sathianathen NJ; Buteau J; Koschel S; Antón Juanilla M; Kapoor J; Azad A; Hofman MS; Murphy DG
BJU Int; 2020 Nov; 126(5):525-535. PubMed ID: 32559353
[TBL] [Abstract][Full Text] [Related]
35. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Sayeg M; Leshch Y; Wester HJ; Baum RP
J Nucl Med; 2016 Oct; 57(Suppl 3):97S-104S. PubMed ID: 27694180
[TBL] [Abstract][Full Text] [Related]
36. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond.
Gafita A; Marcus C; Kostos L; Schuster DM; Calais J; Hofman MS
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35609224
[TBL] [Abstract][Full Text] [Related]
37.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
38. Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
Yamamichi G; Kato T; Watabe T; Hatano K; Uemura M; Nonomura N
Anticancer Res; 2024 Mar; 44(3):879-888. PubMed ID: 38423627
[TBL] [Abstract][Full Text] [Related]
39.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
40. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
